Patents Assigned to Urocor, Inc.
  • Patent number: 7332270
    Abstract: Disclosed are diagnostic techniques for the detection of human disease states that affect gene expression in peripheral leukocytes. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in the peripheral blood of individuals with such a disease state compared to normal healthy individuals. The invention further relates to methods for detection of protein species that are differentially expressed in the peripheral blood of individuals with such a disease state compared to normal healthy individuals. Genetic probes, antibody probes and methods useful in monitoring the progression and diagnosis of two specific disease states, prostatic cancer and breast cancer, are described.
    Type: Grant
    Filed: September 11, 2000
    Date of Patent: February 19, 2008
    Assignee: Urocor, Inc.
    Inventors: David Ralph, Gang An, S. Mark O'Hara, Robert Veltri
  • Publication number: 20030050470
    Abstract: Disclosed are diagnostic techniques for the detection of human prostate, bladder and breast cancer. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate, bladder and breast cancer are described. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in prostate, bladder and breast cancer compared to normal human prostate, benign prostatic hyperplasia, or normal bladder or breast tissue.
    Type: Application
    Filed: October 10, 2001
    Publication date: March 13, 2003
    Applicant: UroCor, Inc.
    Inventors: Gang An, S. Mark O'Hara, David Ralph, Robert Veltri
  • Publication number: 20030017472
    Abstract: Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. Methods of treatment for prostate cancer utilizing antisense constructs or antibodies specific for UC41 gene products are also described.
    Type: Application
    Filed: September 25, 2001
    Publication date: January 23, 2003
    Applicant: UROCOR, INC.
    Inventors: Gang An, Robert Veltri
  • Patent number: 6463438
    Abstract: A neural network is used in a system to detect abnormalities in cells, including cancer in bladder tissue cells. The system has an image analysis system for generating data representative of imaging variables from an image of stained cells. The set of data is provided to a neural network which has been trained to detect abnormalities from known tissue cells with respect to the data from the same set of imaging variables. A conventional sigmoid-activated neural network, or alternatively, a hybrid neural network having a combination of sigmoid, gaussian and sinusoidal activation functions may be utilized. The trained neural network applies a set of weight factors obtained during training to the data to classify the unknown tissue cell as normal or abnormal.
    Type: Grant
    Filed: June 3, 1994
    Date of Patent: October 8, 2002
    Assignee: Urocor, Inc.
    Inventors: Robert W. Veltri, Kaveh Ashenayi, Ying Hu, Gerard J. O'Dowd
  • Publication number: 20020068281
    Abstract: Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. Methods of treatment for prostate cancer utilizing antisense constructs or antibodies specific for UC41 gene products are also described.
    Type: Application
    Filed: January 2, 2001
    Publication date: June 6, 2002
    Applicant: UROCOR, INC.
    Inventors: Gang An, Robert Veltri
  • Patent number: 6369195
    Abstract: Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. Methods of treatment for prostate cancer utilizing antisense constructs or antibodies specific for UC41 gene products are also described.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: April 9, 2002
    Assignee: Urocor, Inc.
    Inventors: Gang An, Robert Veltri
  • Patent number: 6218529
    Abstract: Disclosed are diagnostic techniques for the detection of human prostate, bladder and breast cancer. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate, bladder and breast cancer are described. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in prostate, bladder and breast cancer compared to normal human prostate, benign prostatic hyperplasia, or normal bladder or breast tissue.
    Type: Grant
    Filed: June 12, 1998
    Date of Patent: April 17, 2001
    Assignee: UroCor, Inc.
    Inventors: Gang An, S. Mark O'Hara, David Ralph, Robert Veltri
  • Patent number: 6190857
    Abstract: Disclosed are diagnostic techniques for the detection of human disease states that affect gene expression in peripheral leukocytes. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in the peripheral blood of individuals with such a disease state compared to normal healthy individuals. The invention further relates to methods for detection of protein species that are differentially expressed in the peripheral blood of individuals with such a disease state compared to normal healthy individuals. Genetic probes, antibody probes and methods useful in monitoring the progression and diagnosis of two specific disease states, prostatic cancer and breast cancer, are described.
    Type: Grant
    Filed: March 24, 1998
    Date of Patent: February 20, 2001
    Assignee: Urocor, Inc.
    Inventors: David Ralph, Gang An, S. Mark O'Hara, Robert Veltri
  • Patent number: 6171796
    Abstract: Disclosed are diagnostic techniques for the detection of human prostate disease. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in metastatic prostate cancer compared to normal human prostate, benign prostatic hyperplasia, and non-metastatic prostate cancer. The invention also relates to probes and methods for evaluating the presence of RNA species that are differentially expressed in the peripheral blood of individuals with the disease state compared to normal healthy individuals. Described are methods of therapeutic use for genes identified as differentially expressed in metastatic prostate cancer, and means for screening pharmaceuticals effective in treatment of prostate cancer.
    Type: Grant
    Filed: August 3, 1999
    Date of Patent: January 9, 2001
    Assignee: Urocor, Inc.
    Inventors: Gang An, Robert W. Vertri
  • Patent number: 6156515
    Abstract: Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. Methods of treatment for prostate cancer utilizing antisense constructs or antibodies specific for UC41 gene products are also described.
    Type: Grant
    Filed: February 9, 1999
    Date of Patent: December 5, 2000
    Assignee: Urocor, Inc.
    Inventors: Gang An, Robert Veltri
  • Patent number: 6090559
    Abstract: Disclosed are diagnostic techniques for the detection of human prostate cancer. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in prostate cancer compared to normal human prostate or benign prostatic hyperplasia.
    Type: Grant
    Filed: October 1, 1998
    Date of Patent: July 18, 2000
    Assignee: Urocor, Inc.
    Inventors: David W. Russell, Anice E. Thigpen
  • Patent number: 5989811
    Abstract: A method for screening individuals at risk for the loss of organ confinement in prostate cancer is disclosed. The method is useful for evaluating cells from patients at risk for recurrence of prostate cancer following surgery for prostate cancer. Specifically, the method uses specific Markovian nuclear texture features, alone or in combination with other biomarkers, to determine whether the cancer will progress or lose organ confinement. In addition, methods of predicting the development of fatal metastatic disease by statistical analysis of selected biomarkers is also disclosed. The invention also contemplates a method that uses a neural network to analyze and interpret cell morphology data. Utilizing Markovian factors and other biomarkers as parameters, the network is first trained with a sets of cell data from known progressors and known non-progressors. The trained network is then used to predict the loss of organ confinement by evaluating patient samples.
    Type: Grant
    Filed: September 29, 1995
    Date of Patent: November 23, 1999
    Assignee: Urocor, Inc.
    Inventors: Robert W. Veltri, M. Craig Miller, Michael P. Bacus, Kaveh Ashenayi
  • Patent number: 5972615
    Abstract: Disclosed are diagnostic techniques for the detection of human prostate disease. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in metastatic prostate cancer compared to normal human prostate, benign prostatic hyperplasia, and non-metastatic prostate cancer. The invention also relates to probes and methods for evaluating the presence of RNA species that are differentially expressed in the peripheral blood of individuals with the disease state compared to normal healthy individuals. Described are methods of therapeutic use for genes identified as differentially expressed in metastatic prostate cancer, and means for screening pharmaceuticals effective in treatment of prostate cancer.
    Type: Grant
    Filed: January 21, 1998
    Date of Patent: October 26, 1999
    Assignee: Urocor, Inc.
    Inventors: Gang An, Robert W. Vertri
  • Patent number: 5882864
    Abstract: Disclosed are diagnostic techniques for the detection of human prostate cancer. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in prostate cancer compared to normal human prostate or benign prostatic hyperplasia.
    Type: Grant
    Filed: July 31, 1996
    Date of Patent: March 16, 1999
    Assignee: Urocor Inc.
    Inventors: Gang An, S. Mark O'Hara, David Ralph, Robert Veltri
  • Patent number: 5861248
    Abstract: Disclosed are diagnostic techniques for the detection of human prostate cancer. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in prostate cancer compared to normal human prostate or benign prostatic hyperplasia.
    Type: Grant
    Filed: March 29, 1996
    Date of Patent: January 19, 1999
    Assignee: Urocor, Inc.
    Inventors: David W. Russell, Anice E. Thigpen
  • Patent number: 5856112
    Abstract: A method for selectively inducing expression of biomarkers for urologic cancers, including prostate and bladder cancer, is disclosed. Tumor cells are cultured using a low shear rotational three-dimensional technique under conditions effective to induce said selective expression. The method is useful for diagnostic and therapeutic applications.
    Type: Grant
    Filed: June 16, 1994
    Date of Patent: January 5, 1999
    Assignee: UroCor, Inc.
    Inventors: Garry M. Marley, Robert W. Veltri